ALZN
ALZN
NASDAQ · Biotechnology

Alzamend Neuro Inc

$1.98
+0.11 (+5.88%)
As of Feb 8, 2:30 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 555.8K 518.1K 501.1K
Net Income 113.5K 116.0K 100.3K
EPS
Profit Margin 20.4% 22.4% 20.0%
Rev Growth -5.3% +6.0% -5.8%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 2.09M 1.93M 2.25M
Total Equity 4.81M 4.86M 5.53M
D/E Ratio 0.43 0.40 0.41
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 245.4K 221.0K 210.9K
Free Cash Flow 70.8K 77.8K 93.1K